EP3585785B1 - Process for the preparation of methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate - Google Patents
Process for the preparation of methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate Download PDFInfo
- Publication number
- EP3585785B1 EP3585785B1 EP18706467.0A EP18706467A EP3585785B1 EP 3585785 B1 EP3585785 B1 EP 3585785B1 EP 18706467 A EP18706467 A EP 18706467A EP 3585785 B1 EP3585785 B1 EP 3585785B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methyl
- formula
- reaction
- dihydro
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AMHDHUVBOKXALL-UHFFFAOYSA-N CN1C(OC)=NNC1=O Chemical compound CN1C(OC)=NNC1=O AMHDHUVBOKXALL-UHFFFAOYSA-N 0.000 description 1
- AGPNYTYVWKNJRH-UHFFFAOYSA-N Cc([s]cc1C(OC)=O)c1S(Cl)(=O)=O Chemical compound Cc([s]cc1C(OC)=O)c1S(Cl)(=O)=O AGPNYTYVWKNJRH-UHFFFAOYSA-N 0.000 description 1
- XSKZXGDFSCCXQX-UHFFFAOYSA-N Cc([s]cc1C(OC)=O)c1S(NC(N(C(N1C)=O)N=C1OC)=O)(=O)=O Chemical compound Cc([s]cc1C(OC)=O)c1S(NC(N(C(N1C)=O)N=C1OC)=O)(=O)=O XSKZXGDFSCCXQX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
- A01N43/06—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings
- A01N43/10—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings with sulfur as the ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
Definitions
- the invention relates to an improved process for the preparation of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl ] -5-methylthiophene-3-carboxylate (known under the common name "Thiencarbazone-methyl”).
- Selected substituted thien-3-yl-sulfonylamino-carbonyltriazolinones such as thiencarbazone-methyl, have a particularly good herbicidal effect.
- reaction auxiliaries disclosed relate to acid binders which can usually be used for such reactions.
- the on page 9 of DE 19933260 A1 mentioned selection also includes potassium tert-butoxide and basic nitrogen compounds such as amines including tributylamine and pyridines such as 2-methylpyridines, 3-methylpyridines, 5-ethyl-2-methylpyridines, 2,6-dimethylpyridines.
- the object of the invention is to provide an improved process for the preparation of substituted thien-3yl-sulfonylamino-carbonyltriazolinones, in particular thiencarbazone-methyl, ie the compound of the formula (I), the improved process being the preparation of the target compound thiencarbazone -methyl should enable high purity and yield.
- the object is achieved by the process according to claim 1 for the preparation of the compound of the formula (I) by reacting the compound of formula (II) with a metal cyanate of the formula (III) MeOCN (III) where Me stands for Li, Na, K or, Cs with the compound of formula (IV) , where the reaction in the presence of an imidazole of the formula (V) , in which the radical R1 is an unsubstituted (C 1 -C 12 ) -alkyl or an unsubstituted benzyl.
- the invention is thus based on the finding that the compound of the formula (I) thiencarbazone-methyl under certain conditions, namely in the presence of an imidazole base substituted in the 1-position or in the presence of a base mixture which has a 1-position substituted imidazole base (N-alkylimidazole) contains, can be prepared directly from 4-methoxycarbonyl-2-methyl-thiophene-3-sulfonic acid chloride (compound of formula (II)) with a high purity and yield.
- the above reaction scheme shows that when the reaction is carried out as a one-pot synthesis, a 4-component system is present at the start of the reaction.
- the core of the present invention relates to the surprising finding that the metal cyanate with the sulfonyl group of the respective thiophene compound (in the above scheme with the methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate of the formula (II)) in the presence of an N-alkylimidazole of the formula (V) reacts selectively to form a sulfonyl isocyanate, and that the substituted thien-3yl-sulfonylamino-carbonyltriazolinone (in the above reaction scheme, the target compound thiencarbazone-methyl (I)) is then formed from this.
- the unexpected selectivity of the reaction shown in the scheme consists in the fact that the triazolinone (IV) only reacts further with the sulfonyl isocyanate to form thiencarbazone-methyl after formation of the sulfonyl isocyanate.
- metal cyanates are strong bases (sodium cyanate (NaOCN), for example, has a pH of 10). At the same time, metal cyanates act as O nucleophiles.
- the O-nucleophilicity of the metal cyanates used according to the invention surprisingly has no effect on the course of the present reaction, i.e. its yield and selectivity.
- N-methylimidazole N-methylimidazole
- the reagents are preferably used in equimolar amounts or in excess.
- Me in compounds of the formula MeOCN (III) stands for Na or for K.
- the most preferred metal cyanate in the process according to the invention is NaOCN.
- per mole of sulfonic acid chloride, ie of the compound of the formula (IV) there are also 1 to 2 Mol, preferably 1 to 1.5 mol, particularly preferably 1 to 1.1 mol.
- the process is carried out in an organic solvent, with non-polar and polar solvents being suitable.
- Suitable non-polar solvents are toluene, chlorobenzene, xylene, methyl tert-butyl ether, methyl isopropyl ether, ethyl acetate, isopropyl acetate and butyl acetate.
- Particularly preferred polar solvents are selected from the group consisting of acetonitrile, butyronitrile, tetrahydrofuran (THF), methyl-THF, dimethoxyethane, sulfolane, dimethylformamide and dimethylacetamide.
- Most preferred solvents are acetonitrile and THF.
- the reactants are preferably reacted in a temperature range from 20 ° to 110 ° over a period (reaction time, reaction time) of 3 hours to 24 hours.
- the reaction of the starting materials in a temperature range from 30 ° to 90 ° is very particularly preferred. Most preferably, the reactants are reacted in a temperature range from 50 ° to 80 °.
- Another aspect of the invention relates to the use of an imidazole of the formula (V) , in which the radical R 1 is an unsubstituted (C 1 -C 12 ) -alkyl or an unsubstituted benzyl, for the preparation of the compound of the formula (I)
- R 1 is an unbranched and unsubstituted (C 1 -C 4 ) -alkyl, ie, methyl, ethyl, n-propyl or n-butyl.
- the production process according to the invention can be carried out as a one-pot process or as a two-stage reaction.
- the active ingredient or its salt precipitates out of the reaction mixture and can simply be filtered off.
- an inorganic base such as LiOH, K 2 CO 3 , NaHCO 3 , NaOH, Na 2 CO 3 , CaCO 3 or KOH
- an inorganic base such as LiOH, K 2 CO 3 , NaHCO 3 , NaOH, Na 2 CO 3 , CaCO 3 or KOH
- the use of NaHCO 3 is preferred. In this way, the active ingredient can be isolated with a very high degree of purity.
- the amount of base to be used depends on how much metal cyanate is used when carrying out the reaction. If only 1 equivalent (eq) of NaOCN is used, 1 eq. Of base is then required to completely convert the active ingredient into the salt (example 1). If you set for example 2 eq of the metal cyanate, for example 2 eq NaOCN, to carry out the reaction, no additional base is necessary (cf. Example 3).
- the isocyanate can be isolated and purified by distillation in vacuo.
- TABLE 1 Tabular comparison of the yields based on LC analysis when using different reaction auxiliaries for the preparation of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1 -yl) carbonyl) sulfamoyl] -5-methylthiophenes-3-carboxylate (thiencarbazone-methyl), in acetonitrile, NaOCN 2 eq. Comparison No.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Die Erfindung betrifft ein verbessertes Verfahren zur Herstellung von Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylat (bekannt unter dem common name "Thiencarbazone-methyl").The invention relates to an improved process for the preparation of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl ] -5-methylthiophene-3-carboxylate (known under the common name "Thiencarbazone-methyl").
Die herbizide Wirkung von substituierten Thien-3-yl-sulfonylaminocarbonyl-triazolinonen ist aus dem Dokument
Eine besonders gute herbizide Wirkung haben ausgewählte substituierte Thien-3-yl-sulfonylamino-carbonyltriazolinone, wie z.B. Thiencarbazone-methyl.Selected substituted thien-3-yl-sulfonylamino-carbonyltriazolinones, such as thiencarbazone-methyl, have a particularly good herbicidal effect.
Aufgrund der guten Wirkung wurde die Verbesserung der Verfahren zur Herstellung der vorgenannten Herbizide, auch im Hinblick auf die Umweltverträglichkeit der Herstellung, zu einem beständigen Bemühen der chemischen Forschung.Because of the good effect, the improvement of the processes for the production of the aforementioned herbicides, also with regard to the environmental compatibility of the production, has become a constant endeavor in chemical research.
Dokument
Im Zusammenhang mit den Verfahrensalternativen (a) bis (e) werden in
Dagegen werden Imidazole in
In Dokument
Jedoch ist das in
Vor diesem Hintergrund besteht die Aufgabe der Erfindung in der Bereitstellung eines verbesserten Verfahrens zur Herstellung von substituierten Thien-3yl-sulfonylamino-carbonyltriazolinonen, insbesondere von Thiencarbazone-methyl, d.h. der Verbindung der Formel (I), wobei das verbesserte Verfahren die Herstellung der Zielverbindung Thiencarbazone-methyl in einer hohen Reinheit und Ausbeute ermöglichen soll.Against this background, the object of the invention is to provide an improved process for the preparation of substituted thien-3yl-sulfonylamino-carbonyltriazolinones, in particular thiencarbazone-methyl, ie the compound of the formula (I), the improved process being the preparation of the target compound thiencarbazone -methyl should enable high purity and yield.
Gelöst wird die Aufgabe durch das Verfahren nach Anspruch 1 zur Herstellung der Verbindung der Formel (I)
MeOCN (III)
, worin Me für Li, Na, K oder, Cs steht mit der Verbindung der Formel (IV)
MeOCN (III)
where Me stands for Li, Na, K or, Cs with the compound of formula (IV)
Überraschend wurde im Zusammenhang mit dem erfindungsgemäßen Verfahren gefunden, dass der Einsatz von alkylsubstitutierten Imidazolen, insbesondere von N-Alkylimidazolen die Herstellung von substituierten Thien-3yl-sulfonylaminocarbonyl-triazolinonen, insbesondere die Herstellung von Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylat(Thiencarbazone-methyl) in einer besonders hohen Reinheit und Ausbeute ermöglicht.Surprisingly, it was found in connection with the process according to the invention that the use of alkyl-substituted imidazoles, in particular of N-alkylimidazoles, the production of substituted thien-3yl-sulfonylaminocarbonyl-triazolinones, in particular the production of methyl 4 - [(4,5-dihydro-3 Methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] -5-methylthiophenes-3-carboxylate (thiencarbazone-methyl) in a particularly high purity and yield enables.
Der Erfindung liegt somit die Erkenntnis zugrunde, dass sich die Verbindung der Formel (I) Thiencarbazone-methyl unter bestimmten Bedingungen, nämlich in Gegenwart einer in 1-Position substituierten Imidazol-Base oder in Gegenwart einer Basen-Mischung, welche eine in 1-Position substituierte Imidazol-Base (N-Alkylimidazol) enthält, direkt aus 4-Methoxycarbonyl-2-methyl-thiophen-3-sulfonsäurechlorid (Verbindung der Formel (II)) mit einer hohen Reinheit und Ausbeute herstellbar ist.The invention is thus based on the finding that the compound of the formula (I) thiencarbazone-methyl under certain conditions, namely in the presence of an imidazole base substituted in the 1-position or in the presence of a base mixture which has a 1-position substituted imidazole base (N-alkylimidazole) contains, can be prepared directly from 4-methoxycarbonyl-2-methyl-thiophene-3-sulfonic acid chloride (compound of formula (II)) with a high purity and yield.
Reaktionsschema:
Das vorstehende Reaktionsschema zeigt, dass bei Durchführung der Reaktion als Eintopfsynthese zu Reaktionsbeginn ein 4-Komponenten-System vorliegt.The above reaction scheme shows that when the reaction is carried out as a one-pot synthesis, a 4-component system is present at the start of the reaction.
Im Fall einer zweistufigen Reaktionsführung wird das Edukt 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on der Formel (IV) erst nach Bildung des Sulfonylisocyanats aus Verbindungen der Formeln (II) und (III) in Gegenwart eines N-Alkylimidazols der Formel (V) zu dem Gemisch zugegeben.In the case of a two-stage reaction, the starting material 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one of the formula (IV) is only added after the sulfonyl isocyanate has been formed from compounds of the formulas ( II) and (III) are added to the mixture in the presence of an N-alkylimidazole of the formula (V).
Die Synthese der Edukte, d.h. die Synthese der Verbindungen der Formel (II) und (IV) im vorgenannten Reaktionsschema, ist in
Es wird vermutet, dass die in 1-Position durch einen Alkylrest substituierten Imidazole (N-Alkylimidazole) bei der Bildung des Sulfonylisocyanats besonders gut als Aktivatoren (= Aktivierungsmittel) und/oder Stabilisatoren bei der Bildung des Sulfonylisocyanats wirken.It is assumed that the imidazoles (N-alkylimidazoles) substituted in the 1-position by an alkyl radical act particularly well as activators (= activating agents) and / or stabilizers in the formation of the sulfonyl isocyanate in the formation of the sulfonyl isocyanate.
Der Kern der vorliegenden Erfindung betrifft jedoch die überraschende Erkenntnis, dass das Metallcyanat mit der Sulfonylgruppe der jeweiligen Thiophenverbindung (die im vorstehenden Schema mit dem Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylate der Formel (II)) in Gegenwart eines N-Alkylimidazols der Formel (V) selektiv zu einem Sulfonylisocyanat reagiert, und dass sich aus diesem anschließend das substituierte Thien-3yl-sulfonylamino-carbonyltriazolinon (im vorstehenden Reaktionsschema die Zielverbindung Thiencarbazone-methyl (I)) bildet.The core of the present invention, however, relates to the surprising finding that the metal cyanate with the sulfonyl group of the respective thiophene compound (in the above scheme with the methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate of the formula (II)) in the presence of an N-alkylimidazole of the formula (V) reacts selectively to form a sulfonyl isocyanate, and that the substituted thien-3yl-sulfonylamino-carbonyltriazolinone (in the above reaction scheme, the target compound thiencarbazone-methyl (I)) is then formed from this.
Die unerwartete Selektivität der im Schema dargestellten Reaktion besteht darin, dass das Triazolinon (IV) erst nach Bildung des Sulfonylisocyanats mit demselben weiter zu Thiencarbazone-methyl, reagiert.The unexpected selectivity of the reaction shown in the scheme consists in the fact that the triazolinone (IV) only reacts further with the sulfonyl isocyanate to form thiencarbazone-methyl after formation of the sulfonyl isocyanate.
Außerdem ist im Hinblick auf den Einsatz eines Metallcyanats bei einer chemischen Reaktion ganz allgemein zu bedenken, dass Metallcyanate starke Basen sind (Natriumcyanat (NaOCN) hat z.B. einen pH von 10). Zugleich wirken Metallcyanate als O-Nukleophile.In addition, with regard to the use of a metal cyanate in a chemical reaction, it should be considered in general that metal cyanates are strong bases (sodium cyanate (NaOCN), for example, has a pH of 10). At the same time, metal cyanates act as O nucleophiles.
In Gegenwart eines N-Alkylimidazols, insbesondere in Gegenwart von N-Methylimidazol, wirkt sich die O-Nukleophilie der erfindungsgemäß eingesetzten Metallcyanate überraschenderweise aber gerade nicht auf den Verlauf der vorliegenden Reaktion, d.h. deren Ausbeute und deren Selektivität aus.In the presence of an N-alkylimidazole, in particular in the presence of N-methylimidazole, the O-nucleophilicity of the metal cyanates used according to the invention surprisingly has no effect on the course of the present reaction, i.e. its yield and selectivity.
Das gilt nicht für den Einsatz anderer basischer Stickstoffverbindungen wie Pyridine, Picoline oder 4-(Dimethylamino)-pyridin (DMAP), die als klassische Aktivatoren für, zum Beispiele, Carbonsäurehalogenide anzusehen sind. Das Gleiche gilt für den Einsatz von anorganischen Basen wie K2CO3 oder Kalium-tert-butylat (KOtBut) die sich ebenfalls als nicht geeignet erwiesen haben.This does not apply to the use of other basic nitrogen compounds such as pyridines, picolines or 4- (dimethylamino) pyridine (DMAP), which are to be regarded as classic activators for, for example, carboxylic acid halides. The same applies to the use of inorganic bases such as K 2 CO 3 or potassium tert-butoxide (KOtBut), which have also proven to be unsuitable.
So wurde durch Beispiel belegt, dass die Thiencarbazone-methyl-Ausbeute bei Anwendung des erfindungsgemäßen Verfahrens im Vergleich zur Durchführung der Reaktion unter Einsatz anderer alternativer basischer Stickstoffverbindungen unerwartet hoch ist.It was demonstrated by example that the thiencarbazone-methyl yield when using the process according to the invention is unexpectedly high compared to carrying out the reaction using other alternative basic nitrogen compounds.
Bevorzugt ist die Durchführung des erfindungsgemäßen Verfahrens in Gegenwart eines Imidazols der Formel (V), worin der Rest R1 ein unsubstituiertes (C1-C6)-Alkyl, oder ein unsubstituiertes Benzyl ist. Die Durchführung des Verfahrens in Gegenwart eines Imidazols der Formel (V), worin der Rest R1 ein substituiertes (C1-C6)-Alkyl, oder ein substituiertes Benzyl ist nicht bevorzugt, liegt jedoch ebenfalls im Rahmen der Erfindung.It is preferred to carry out the process according to the invention in the presence of an imidazole of the formula (V) in which the radical R 1 is an unsubstituted (C 1 -C 6 ) -alkyl or an unsubstituted benzyl. Carrying out the process in the presence of an imidazole of the formula (V) in which the radical R 1 is a substituted (C 1 -C 6 ) -alkyl or a substituted benzyl is not preferred, but is likewise within the scope of the invention.
Besonders bevorzugt ist die Durchführung des erfindungsgemäßen Verfahrens in Gegenwart eines Imidazols der Formel (V), worin der Rest R1 ein unsubstituiertes (C1-C4)-Alkyl ist. Unverzweigte (C1-C4)-Alkyl, d.h. Methyl, Ethyl, n-Propyl oder n-Butyl für R1 sind ganz besonders bevorzugt.It is particularly preferred to carry out the process according to the invention in the presence of an imidazole of the formula (V) in which the radical R 1 is an unsubstituted (C 1 -C 4 ) -alkyl. Unbranched (C 1 -C 4 ) -alkyl, ie methyl, ethyl, n-propyl or n-butyl for R 1, are very particularly preferred.
Am meisten bevorzugt ist die Durchführung des erfindungsgemäßen Verfahrens in Gegenwart von N-Methylimidazol (NMI), d.h. wenn. der Rest R1 in Formel (V) für Methyl steht.It is most preferred to carry out the process according to the invention in the presence of N-methylimidazole (NMI), ie when. the radical R 1 in formula (V) represents methyl.
Zur Herstellung der Verbindung der Formel (I) werden bei dem erfindungsgemäßen Verfahren die Reagenzien bevorzugt äquimolar oder im Überschuss eingesetzt.To prepare the compound of the formula (I) in the process according to the invention, the reagents are preferably used in equimolar amounts or in excess.
In allgemein werden je Mol Sulfonsäurechlorid, d.h. der Verbindung der Formel (II) 1 bis 2,5 Mol, bevorzugt 1 bis 2 Mol, besonders bevorzugt 1 bis 1,8 Mol des Metallcyanats der Formel MeOCN (III) eingesetzt. Aber auch der Einsatz größerer Überschüsse der Verbindung der Formel (III) liegt im Rahmen der Erfindung.In general, 1 to 2.5 mol, preferably 1 to 2 mol, particularly preferably 1 to 1.8 mol, of the metal cyanate of the formula MeOCN (III) are used per mole of sulfonic acid chloride, ie the compound of the formula (II). However, the use of relatively large excesses of the compound of the formula (III) is also within the scope of the invention.
In einer bevorzugten Ausführungsform steht Me in Verbindungen der Formel MeOCN (III) für Na oder für K. Das bei dem erfindungsgemäßen Verfahren am meisten bevorzugte Metallcyanat ist NaOCN. Weiterhin werden im Allgemeinen je Mol Sulfonsäurechlorid, d.h. von der Verbindung der Formel (IV) (5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on) ebenfalls 1 bis 2 Mol, bevorzugt 1 bis 1,5 Mol, besonders bevorzugt 1 bis 1,1 Mol eingesetzt.In a preferred embodiment, Me in compounds of the formula MeOCN (III) stands for Na or for K. The most preferred metal cyanate in the process according to the invention is NaOCN. Furthermore, per mole of sulfonic acid chloride, ie of the compound of the formula (IV) (5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one), there are also 1 to 2 Mol, preferably 1 to 1.5 mol, particularly preferably 1 to 1.1 mol.
Aber auch der Einsatz größerer Überschüsse der Verbindung der Formel (IV) liegt im Rahmen der Erfindung.However, the use of relatively large excesses of the compound of the formula (IV) is also within the scope of the invention.
Die Durchführung des Verfahrens erfolgt in einem organischen Lösungsmittel, wobei unpolare und polare Lösungsmittel geeignet sind.The process is carried out in an organic solvent, with non-polar and polar solvents being suitable.
Als unpolare Lösungsmittel kommen Toluol, Chlorbenzol, Xylol, Methyl-tert-butylether, Methylisopropylether, Ethylacetat, Isopropylacetat und Butylacetat in Frage.Suitable non-polar solvents are toluene, chlorobenzene, xylene, methyl tert-butyl ether, methyl isopropyl ether, ethyl acetate, isopropyl acetate and butyl acetate.
Besonders bevorzugte polare Lösungsmittel sind ausgewählt aus der Gruppe bestehend aus Acetonitril, Butyronitril, Tetrahydrofuran (THF), Methyl-THF, Dimethoxyethan, Sulfolan, Dimethylformamid und Dimethylacetamid.Particularly preferred polar solvents are selected from the group consisting of acetonitrile, butyronitrile, tetrahydrofuran (THF), methyl-THF, dimethoxyethane, sulfolane, dimethylformamide and dimethylacetamide.
Am meisten bevorzugt als Lösungsmittel sind Acetonitril und THF.Most preferred solvents are acetonitrile and THF.
Auch Gemische von verschiedenen Lösungsmitteln können eingesetzt werden.Mixtures of different solvents can also be used.
Bevorzugt erfolgt die Umsetzung der Edukte in einem Temperaturbereich von 20° bis 110° über eine Dauer (Reaktionszeit, Reaktionsdauer) von 3 Stunden bis 24 Stunden.The reactants are preferably reacted in a temperature range from 20 ° to 110 ° over a period (reaction time, reaction time) of 3 hours to 24 hours.
Ganz besonders bevorzugt ist die Umsetzung der Edukte in einem Temperaturbereich von 30° bis 90°. Am meisten bevorzugt erfolgt die Umsetzung der Edukte in einem Temperaturbereich von 50° bis 80°.The reaction of the starting materials in a temperature range from 30 ° to 90 ° is very particularly preferred. Most preferably, the reactants are reacted in a temperature range from 50 ° to 80 °.
Ein weiterer Aspekt der Erfindung betrifft die Verwendung eines Imidazols der Formel (V)
Bevorzugt ist die Verwendung eines Imidazols der Formel (V), worin R1 ein unsubstituiertes (C1-C4)-Alkyl steht.The use of an imidazole of the formula (V) in which R 1 is an unsubstituted (C 1 -C 4 ) -alkyl is preferred.
Besonders bevorzugt ist die Verwendung eines Imidazols der Formel (V), worin R1 für ein unverzweigtes und unsubstituiertes (C1-C4)-Alkyl, d.h. für Methyl, Ethyl, n-Propyl oder n-Butyl steht.It is particularly preferred to use an imidazole of the formula (V) in which R 1 is an unbranched and unsubstituted (C 1 -C 4 ) -alkyl, ie, methyl, ethyl, n-propyl or n-butyl.
Am meisten bevorzugt ist die Verwendung eines Imidazols der Formel (V), worin R1 für Methyl steht.Most preferred is the use of an imidazole of the formula (V) in which R 1 is methyl.
Das erfindungsgemäße Herstellungsverfahren kann als Eintopfverfahren oder als zweistufige Reaktion durchgeführt werden.The production process according to the invention can be carried out as a one-pot process or as a two-stage reaction.
Beim Eintopfverfahren werden alle Chemikalien in einem organischen Lösemittel gemischt und dann unter Rühren erhitzen. Um die Exothermie der Reaktion besser zu kontrollieren, ist es auch empfehlenswert, die Reagenzien der Formel (III), (IV) und (V) in z. B. Acetonitril vorzulegen, um dann das Sulfonylchlorid der Formel (II) als Lösung bei der Rektionstemperatur langsam hinzu zu dosieren.In the one-pot process, all chemicals are mixed in an organic solvent and then heated while stirring. In order to better control the exothermicity of the reaction, it is also advisable to use the reagents of the formula (III), (IV) and (V) in e.g. B. to submit acetonitrile in order to then slowly add the sulfonyl chloride of the formula (II) as a solution at the reaction temperature.
Während der Reaktion fällt der Wirkstoff oder dessen Salz aus dem Reaktionsgemisch aus und kann einfach ab filtriert werden.During the reaction, the active ingredient or its salt precipitates out of the reaction mixture and can simply be filtered off.
Besonders vorteilhaft ist es, am Ende der Reaktion eine anorganische Base wie z.B. LiOH, K2CO3, NaHCO3, NaOH, , Na2CO3, CaCO3 oder KOH zu dem Gemisch zuzusetzen, um den Wirkstoff als unlösliches Li, Na, K oder Ca-Salz zu isolieren. Bevorzugt ist die Verwendung von NaHCO3. Auf diese Weise gelingt die Isolierung des Wirkstoffes in sehr hoher Reinheit.It is particularly advantageous to add an inorganic base such as LiOH, K 2 CO 3 , NaHCO 3 , NaOH, Na 2 CO 3 , CaCO 3 or KOH to the mixture at the end of the reaction in order to convert the active ingredient as insoluble Li, Na, Isolate K or Ca salt. The use of NaHCO 3 is preferred. In this way, the active ingredient can be isolated with a very high degree of purity.
Die Menge der einzusetzenden Base hängt davon ab, wieviel Metallcyanat bei Durchführung der Reaktion eingesetzt wird. Bei Einsatz von nur 1 Äquivalent (Eq) NaOCN ist dann entsprechend 1 Eq. Base notwendig, um den Wirkstoff komplett in das Salz zu überführen (Beispiel 1). Setzt man beispielsweise 2 Eq des Metallcyanats, z.B. 2 Eq NaOCN, zur Durchführung der Reaktion ein, so ist keine zusätzliche Base notwendig (vgl. Beispiel 3).The amount of base to be used depends on how much metal cyanate is used when carrying out the reaction. If only 1 equivalent (eq) of NaOCN is used, 1 eq. Of base is then required to completely convert the active ingredient into the salt (example 1). If you set for example 2 eq of the metal cyanate, for example 2 eq NaOCN, to carry out the reaction, no additional base is necessary (cf. Example 3).
Durch Behandlung des Salzes mit einer Säure (z.B. HCl, H2SO4) wird der Wirkstoff freigesetzt und nach der Filtration isoliert.Treatment of the salt with an acid (eg HCl, H 2 SO 4 ) releases the active ingredient and isolates it after filtration.
Es ist auch möglich, zuerst die Verbindung der Formel (II) mit MeOCN in Gegenwart der Verbindung der Formel (V) umzusetzen, um das Sulfonylisocynat der Formel (VI) herzustellen. In einem zweiten Schritt wird dann das Sulfonylisocyanat, ggf. ohne vorherige Isolierung, mit 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on der Formel (IV) umgesetzt.It is also possible to first react the compound of the formula (II) with MeOCN in the presence of the compound of the formula (V) in order to prepare the sulfonyl isocyanate of the formula (VI). In a second step, the sulfonyl isocyanate is then reacted with 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one of the formula (IV), if necessary without prior isolation.
Die Analyse, Identifizierung und Gehaltsbestimmung von Sulfonylisocynat nach dem Schritt 1 basiert auf der Derivatisierung mit Methanol zum entsprechenden Carbamat der Formel (VII).
Falls notwendig, kann das Isocyanat isoliert und durch Destillation im Vakuum gereinigt werden.
Die oben stehende Tabelle belegt, dass die Thiencarbazone-methyl-Ausbeute bei Anwendung des erfindungsgemäßen Verfahrens bei Einsatz von N-Butylimidazol und N-Methylimidazol im Vergleich zu anderen Stickstoffbasen unerwartet hoch ist. Dagegen ist beim vergleichenden Einsatz der Stickstoffbase Tributylamin das durch Flüssigchromatographie (LC) nachweisbare Zielprodukt Thiencarbazone-methyl in einem niedrigen %-Bereich. Bei Einsatz des Säurebindemittels Kalium-tert-butylat (KOtBut) ist ein Produktnachweis gar nicht möglich.The table above shows that the thiencarbazone-methyl yield when using the method according to the invention when using N-butylimidazole and N-methylimidazole is unexpectedly high compared to other nitrogen bases. In contrast, when comparing the nitrogen base tributylamine, the target product thiencarbazone-methyl, which can be detected by liquid chromatography (LC), is in a low% range. If the acid binding agent potassium tert-butylate (KOtBut) is used, product verification is not possible at all.
25.4 g von Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylat, 6,5 g NaOCN, 12,9 g N-Methylimidazol und 12,9 g 5-Methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on wird in 200 ml Acetonitril vorgelegt und auf 70°C erhitzt. Das Gemisch wurde unter Rühren 12 Std bei dieser Temperatur erhitzt und auf 20°C abgekühlt.25.4 g of methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate, 6.5 g NaOCN, 12.9 g N-methylimidazole and 12.9 g 5-methoxy-4-methyl-2,4-dihydro -3H-1,2,4-triazol-3-one is placed in 200 ml of acetonitrile and heated to 70.degree. The mixture was heated at this temperature for 12 hours with stirring and cooled to 20 ° C.
Dem Gemisch wurden 8,5 g NaHCO3 zugesetzt und die Suspension wurde 3 Std bei 20°C nachgerührt. Der Niederschlag wurde abfiltriert, mit 50 ml 10-iger % HCl und 100 ml Wasser gewaschen und bei 50°C getrocknet. Man erhielt 31,6 g des_Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylats, 80 % der Theorie mit einem Schmelzpunkt von 201°C, und einer Reinheit von 99 %.8.5 g of NaHCO 3 were added to the mixture and the suspension was stirred at 20 ° C. for 3 hours. The precipitate was filtered off, washed with 50 ml of 10% HCl and 100 ml of water and dried at 50.degree. 31.6 g was obtained des_Methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] -5 methylthiophene-3-carboxylate, 80% of theory with a melting point of 201 ° C, and a purity of 99%.
25.4 g. von Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylat, 11,7 g NaOCN, 8,2 g N-Methylimidazol und 12,9 g 5-Methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on wird in 220 ml Acetonitril vorgelegt und auf 70°C erhitzt. Das Gemisch wurde unter Rühren 18 Std bei dieser Temperatur erhitzt und auf 20°C abgekühlt. Dem Gemisch wurden 1,7 g NaHCO3 zugesetzt und die Suspension wurde 2 Std bei 20°C nachgerührt. Das Reaktionsgemisch wurde auf 60°C erhitzt, der Niederschlag wurde ab filtriert und mit 50 ml Acetonitril gewaschen. Danach wurde der Niederschlag mit 70 ml 20-iger % H2SO4, 100 ml heißem (70°C) Wasser und 50 ml Acetone gewaschen und bei 50°C getrocknet. Man erhielt 31,4 g des Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylats, 79 % der Theorie mit einer Reinheit von 98 %.25.4 g. of methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate, 11.7 g NaOCN, 8.2 g N-methylimidazole and 12.9 g 5-methoxy-4-methyl-2,4-dihydro-3H -1,2,4-triazol-3-one is placed in 220 ml of acetonitrile and heated to 70.degree. The mixture was heated with stirring at this temperature for 18 hours and cooled to 20 ° C. 1.7 g of NaHCO 3 were added to the mixture and the suspension was stirred at 20 ° C. for 2 hours. The reaction mixture was heated to 60 ° C., the precipitate was filtered off and washed with 50 ml of acetonitrile. The precipitate was then washed with 70 ml of 20% H 2 SO 4 , 100 ml of hot (70 ° C.) water and 50 ml of acetone and dried at 50 ° C. This gave 31.4 g of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] - 5-methylthiophen-3-carboxylate, 79% of theory with a purity of 98%.
25.4 g von Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylat, 13 g NaOCN, 12,9 g N-Methylimidazol und 12,9 g 5-Methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on wird in 200 ml Acetonitril vorgelegt und auf 70°C erhitzt. Das Gemisch wurde unter Rühren 12 Std bei dieser Temperatur erhitzt und auf 20°C abgekühlt.25.4 g of methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate, 13 g NaOCN, 12.9 g N-methylimidazole and 12.9 g 5-methoxy-4-methyl-2,4-dihydro-3H -1,2,4-triazol-3-one is in 200 ml Submitted acetonitrile and heated to 70 ° C. The mixture was heated at this temperature for 12 hours with stirring and cooled to 20 ° C.
Der Niederschlag wurde abfiltriert, mit 50 ml 10-iger % HCl und 100 ml Wasser gewaschen und bei 50°C getrocknet. Man erhielt 33,6 g des Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylats, 84,4 % der Theorie mit einer Reinheit von 98 %.The precipitate was filtered off, washed with 50 ml of 10% HCl and 100 ml of water and dried at 50.degree. This gave 33.6 g of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] - 5-methylthiophen-3-carboxylate, 84.4% of theory with a purity of 98%.
25.4 g von Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylate, 6,5 g NaOCN, 12,9 g N-Methylimidazol wurden in 150 ml Acetonitril vorgelegt und das Gemisch 4 Std bei 50°C erhitzt. Die Suspension wurde unter Argon über eine Glassfritte filtriert und dem Filtrat 12.5 g 5-Methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on zugegeben. Anschließend wurde das Gemisch 8 Std bei 70°C erhitzt und auf 20°C abgekühlt.25.4 g of methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate, 6.5 g of NaOCN, 12.9 g of N-methylimidazole were placed in 150 ml of acetonitrile and the mixture was heated at 50 ° C. for 4 hours. The suspension was filtered through a glass frit under argon and 12.5 g of 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one were added to the filtrate. The mixture was then heated at 70 ° C. for 8 hours and cooled to 20 ° C.
Dem Gemisch wurden 8 g NaHCO3 und 1 ml Wasser zugesetzt und die Suspension wurde 3 Std nachgerührt. Der Niederschlag wurde abfiltriert, mit 50 ml 10 %-iger HCl und 100 ml Wasser gewaschen und bei 50°C getrocknet. Man erhielt 29,6 g des Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylats 75,6 % der Theorie mit einem Schmelzpunkt 201°C und einer Reinheit von >99 %.8 g of NaHCO 3 and 1 ml of water were added to the mixture and the suspension was stirred for 3 hours. The precipitate was filtered off, washed with 50 ml of 10% HCl and 100 ml of water and dried at 50.degree. This gave 29.6 g of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] - 5-methylthiophene-3-carboxylate 75.6% of theory with a melting point of 201 ° C. and a purity of> 99%.
25.4 g von Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylate, 11,7 g NaOCN, 12,3 g N-Methylimidazol wurden in 150 ml Acetonitril vorgelegt und das Gemisch 4 Std bei 50°C erhitzt. Die Suspension wurde unter Argon über eine Glassfritte filtriert und dem Filtrat 12.5 g 5-Methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on zugegeben. Anschließend wurde das Gemisch 12 Std bei 70°C erhitzt und auf 20°C abgekühlt.25.4 g of methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate, 11.7 g of NaOCN, 12.3 g of N-methylimidazole were placed in 150 ml of acetonitrile and the mixture was heated at 50 ° C. for 4 hours. The suspension was filtered through a glass frit under argon and 12.5 g of 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one were added to the filtrate. The mixture was then heated at 70 ° C. for 12 hours and cooled to 20 ° C.
Dem Gemisch wurden 1.7 g NaHCO3 und 1 ml Wasser zugesetzt und die Suspension wurde 3 Std nachgerührt. Der Niederschlag wurde abfiltriert, mit 50 ml 10 %-iger HCl und 100 ml heißem Wasser gewaschen und bei 50°C getrocknet. Man erhielt 30,5 g des Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylats 77 % der Theorie mit einer Reinheit von 98 %.1.7 g of NaHCO 3 and 1 ml of water were added to the mixture and the suspension was stirred for 3 hours. The precipitate was filtered off, washed with 50 ml of 10% HCl and 100 ml of hot water and dried at 50.degree. This gave 30.5 g of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] - 5-methylthiophen-3-carboxylate 77% of theory with a purity of 98%.
25.4 g von Methyl-4-(chlorsulfonyl)-5-methylthiophene-3-carboxylat, 6,5 g NaOCN, 12,9 g N-Methylimidazol wurden in 150 ml Acetonitril vorgelegt und das Gemisch 4 Std bei 50°C erhitzt. Die Suspension wurde unter Argon über eine Glassfritte filtriert und mit 30 ml Methanol versetzt. Nach 1 Std wurde die Lösung komplett eingeengt und der Niederschlag mit Waser gewaschen und getrocknet. Man erhielt 24 g Methyl 4-(methoxycarbonylsulfamoyl)-5-methyl-thiophen-3-carboxylat (1H NMR: (d6 DMSO) 2,72 (s), 3,62 (s), 3,79 (s), 8.01 (s), 12.01 (s) ppm).25.4 g of methyl 4- (chlorosulfonyl) -5-methylthiophen-3-carboxylate, 6.5 g of NaOCN, 12.9 g of N-methylimidazole were placed in 150 ml of acetonitrile and the mixture was heated at 50 ° C. for 4 hours. The suspension was filtered through a glass frit under argon, and 30 ml of methanol were added. After 1 hour, the solution was completely concentrated and the precipitate was washed with water and dried. 24 g of methyl 4- (methoxycarbonylsulfamoyl) -5-methyl-thiophene-3-carboxylate were obtained ( 1 H NMR: (d 6 DMSO) 2.72 (s), 3.62 (s), 3.79 (s) , 8.01 (s), 12.01 (s) ppm).
Claims (15)
- Method for preparing the compound of the formula (I)
by reacting the compound of the formula (II) with a metal cyanate of the formula (III)
MeOCN (III)
where Me is Li, Na, K or Cs
and
with the compound of the formula (IV) wherein the reaction is carried out in the presence of an imidazole of the formula (V) where the radical R1 is an unsubstituted (C1-C12) -alkyl or an unsubstituted benzyl. - Method for preparing compounds of the formula (I) according to Claim 1, characterized in that R1 is an unsubstituted (C1-C6)-alkyl or an unsubstituted benzyl.
- Method for preparing compounds of the formula (I) according to Claim 2, characterized in that R1 is an unsubstituted (C1-C4)-alkyl.
- Method for preparing compounds of the formula (I) according to Claim 3, characterized in that R1 is methyl, ethyl, n-propyl or n-butyl.
- Method for preparing compounds of the formula (I) according to Claim 4, characterized in that R1 is methyl.
- Method for preparing compounds of the formula (I) according to any of Claims 1 to 5, characterized in that Me in compounds of the formula MeOCN (III) is Na or K.
- Method for preparing compounds of the formula (I) according to any of Claims 1 to 6, characterized in that the reaction is carried out in a polar solvent selected from the group consisting of acetonitrile, butyronitrile, tetrahydrofuran (THF), methyl-THF, dimethoxyethane, sulfolane, dimethylformamide and dimethylacetamide.
- Method for preparing compounds of the formula (I) according to any of Claims 1 to 6, characterized in that the reaction is carried out in a solvent mixture consisting of acetonitrile and THF.
- Method for preparing compounds of the formula (I) according to any of Claims 1 to 8, characterized in that the reaction of the reactants is conducted- in a temperature range of 20° to 110° and- in a reaction time of 3 hours to 24 hours.
- Method for preparing compounds of the formula (I) according to Claim 9, characterized in that the reaction of the reactants is conducted in a temperature range of 30° to 90°.
- Method for preparing compounds of the formula (I) according to Claim 10, characterized in that the reaction of the reactants is conducted in a temperature range of 50° to 80°.
- Use of an imidazole of the formula (V) according to Claim 12, characterized in that R1 is an unsubstituted (C1-C4)-alkyl.
- Use of an imidazole of the formula (V) according to Claim 13, characterized in that R1 is methyl, ethyl, n-propyl or n-butyl.
- Use of an imidazole of the formula (V) according to Claim 14, characterized in that R1 is methyl.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17157615 | 2017-02-23 | ||
| PCT/EP2018/053771 WO2018153767A1 (en) | 2017-02-23 | 2018-02-15 | Process for the preparation of methyl-4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazole-1-yl)carbonyl)sulphamoyl]-5-methylthiophene-3-carboxylate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3585785A1 EP3585785A1 (en) | 2020-01-01 |
| EP3585785B1 true EP3585785B1 (en) | 2021-01-27 |
Family
ID=58158923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18706467.0A Active EP3585785B1 (en) | 2017-02-23 | 2018-02-15 | Process for the preparation of methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10906893B2 (en) |
| EP (1) | EP3585785B1 (en) |
| JP (1) | JP7001699B2 (en) |
| KR (1) | KR102520302B1 (en) |
| CN (1) | CN110352193B (en) |
| BR (1) | BR112019017396B1 (en) |
| DK (1) | DK3585785T3 (en) |
| ES (1) | ES2857821T3 (en) |
| IL (1) | IL268358B (en) |
| MX (1) | MX2019009998A (en) |
| TW (1) | TWI668211B (en) |
| WO (1) | WO2018153767A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024200331A2 (en) | 2023-03-29 | 2024-10-03 | Bayer Aktiengesellschaft | Method for producing methyl-4-isocyanatosulfonyl-5-methyl-thiophene-3-carboxylate |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3139250A1 (en) * | 1981-10-02 | 1983-04-21 | Basf Ag, 6700 Ludwigshafen | PLANT GROWTH REGULATING AZOLYLALKYL-2,3-DIHYDROBENZOFURANES AND THEIR USE |
| DE4017338A1 (en) * | 1990-05-30 | 1991-12-05 | Bayer Ag | SULFONYLATED CARBONIC ACID AMIDES |
| DE19650196A1 (en) * | 1996-12-04 | 1998-06-10 | Bayer Ag | Thienylsulfonylamino (thio) carbonyl compounds |
| DE19933260A1 (en) * | 1999-07-15 | 2001-01-18 | Bayer Ag | Substituted thien-3-yl-sulfonylamino (thio) carbonyl-triazolin (thi) one |
| AU2003302106A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| DE102004063192A1 (en) * | 2004-12-29 | 2006-07-13 | Bayer Cropscience Ag | Process for the preparation of substituted thiophenesulfonyl isocyanates |
-
2018
- 2018-02-13 TW TW107105126A patent/TWI668211B/en not_active IP Right Cessation
- 2018-02-15 MX MX2019009998A patent/MX2019009998A/en unknown
- 2018-02-15 KR KR1020197024548A patent/KR102520302B1/en active Active
- 2018-02-15 EP EP18706467.0A patent/EP3585785B1/en active Active
- 2018-02-15 BR BR112019017396-0A patent/BR112019017396B1/en not_active IP Right Cessation
- 2018-02-15 JP JP2019545766A patent/JP7001699B2/en not_active Expired - Fee Related
- 2018-02-15 CN CN201880011300.6A patent/CN110352193B/en not_active Expired - Fee Related
- 2018-02-15 WO PCT/EP2018/053771 patent/WO2018153767A1/en not_active Ceased
- 2018-02-15 ES ES18706467T patent/ES2857821T3/en active Active
- 2018-02-15 US US16/486,516 patent/US10906893B2/en not_active Expired - Fee Related
- 2018-02-15 DK DK18706467.0T patent/DK3585785T3/en active
-
2019
- 2019-07-30 IL IL268358A patent/IL268358B/en active IP Right Grant
Non-Patent Citations (1)
| Title |
|---|
| None * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020508322A (en) | 2020-03-19 |
| JP7001699B2 (en) | 2022-01-20 |
| IL268358A (en) | 2019-09-26 |
| ES2857821T3 (en) | 2021-09-29 |
| DK3585785T3 (en) | 2021-03-29 |
| IL268358B (en) | 2021-01-31 |
| EP3585785A1 (en) | 2020-01-01 |
| CN110352193B (en) | 2022-11-11 |
| KR20190121770A (en) | 2019-10-28 |
| US20200048234A1 (en) | 2020-02-13 |
| TWI668211B (en) | 2019-08-11 |
| BR112019017396A2 (en) | 2020-03-31 |
| WO2018153767A1 (en) | 2018-08-30 |
| BR112019017396B1 (en) | 2023-02-14 |
| US10906893B2 (en) | 2021-02-02 |
| CN110352193A (en) | 2019-10-18 |
| KR102520302B1 (en) | 2023-04-10 |
| TW201833088A (en) | 2018-09-16 |
| MX2019009998A (en) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0277317A1 (en) | Nitro derivatives of 2-iminoimidazolidines and 2-iminotetrahydropyrimidines | |
| EP1616863A1 (en) | Process for the preparation of fluorinated aromatic compounds | |
| EP3585785B1 (en) | Process for the preparation of methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate | |
| EP0008057B1 (en) | Process for the preparation of n-substituted alpha-haloacetanilides | |
| CH632501A5 (en) | METHOD FOR PRODUCING 1-AZOLYL-3,3-DIMETHYL-1-PHENOXY-BUTAN-2-ONEN. | |
| DE69401486T2 (en) | Process for the preparation of 2-cyanoimidazole derivatives | |
| EP0726258A1 (en) | Process and intermediates for the preparation of triazolinones | |
| DE69411783T2 (en) | Process for the preparation of sulfonylurea derivatives | |
| EP0659746B1 (en) | Process for the preparation of sulfonylaminocarbonyl-triazolinones | |
| EP3577114B1 (en) | Method for the preparation of halogenated imidazopyridine derivatives | |
| EP1833813B1 (en) | Method for the production of substituted thiophenesulfonyl isocyanates | |
| DE19904310A1 (en) | Process for the preparation of heterocyclic compounds | |
| DE19610785A1 (en) | Process for the preparation of substituted aromatic thiocarboxamides | |
| EP0047941B1 (en) | Process for the production and purification of phenoxy-azolyl-butanone derivatives | |
| EP2233469B1 (en) | Method for coupling halogen-substituted aromatic substances with trialkylsilyl-substituted heteroatom-containing organic compounds | |
| DE3723230A1 (en) | Novel triazole derivatives, their preparation and their use | |
| DE3916207A1 (en) | METHOD AND NEW INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF TRIAZOLONE DERIVATIVES | |
| DE2332323A1 (en) | N-2-aminophenyl N'-alkoxycarbonyl S-alkylisothioureas - prepd. by reacting N-(chloromercaptomethylene)carbamic acid esters with amines | |
| EP0470430A1 (en) | Process for the preparation of oxyguanidins | |
| EP0416319A2 (en) | Process for the preparation of sulfonylisoureas | |
| WO2018141751A1 (en) | Production of n-substituted aromatic hydroxylamine | |
| DE1620093B (en) | 1-square bracket on furfurylideneamino square bracket for -hydantoine- or -imidazolidinone and process for their preparation | |
| DE3443597A1 (en) | SUBSTITUTED AZOLYLALKYL-PYRIDINYL ETHERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20190923 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20201026 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1358261 Country of ref document: AT Kind code of ref document: T Effective date: 20210215 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 502018003809 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: FI Ref legal event code: FGE |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210325 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210427 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210427 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210527 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2857821 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210929 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210527 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 502018003809 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210215 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20211028 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210215 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210527 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230123 Year of fee payment: 6 Ref country code: FI Payment date: 20230220 Year of fee payment: 6 Ref country code: ES Payment date: 20230310 Year of fee payment: 6 Ref country code: DK Payment date: 20230213 Year of fee payment: 6 Ref country code: CH Payment date: 20230307 Year of fee payment: 6 Ref country code: AT Payment date: 20230125 Year of fee payment: 6 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230126 Year of fee payment: 6 Ref country code: GB Payment date: 20230119 Year of fee payment: 6 Ref country code: DE Payment date: 20230117 Year of fee payment: 6 Ref country code: BE Payment date: 20230125 Year of fee payment: 6 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230503 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230125 Year of fee payment: 6 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20180215 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 502018003809 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20240229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210127 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20240301 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240215 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 1358261 Country of ref document: AT Kind code of ref document: T Effective date: 20240215 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20240215 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240215 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240215 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240215 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240301 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240301 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20240229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240903 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240215 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240215 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240903 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240215 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20250331 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240216 |